Journal
IMMUNOTHERAPY
Volume 2, Issue 5, Pages 655-661Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.10.53
Keywords
antibody therapy; innate immunity; prophylaxis; RSV; therapeutics treatment
Categories
Funding
- National Institutes of Health [5RO1AI06275-03]
- National Institutes of Health through Georgia Research Alliance
- Cooperative Research and Development Agreement between Trellis Bioscience, University of Georgia and Centers for Disease Control and Prevention
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI088744, R01AI069275] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in infants and young children and an important pathogen of the elderly and immune suppressed. The only intervention currently available is a monoclonal antibody against the RSV fusion protein, which has shown utility as a prophylactic for high-risk premature infants, but which has not shown postinfection therapeutic efficacy in the specific RSV-infected populations studied. Thus, for the major susceptible populations, there remains a great need for effective treatment. Recent results support monoclonal antibody targeting of the RSV G-protein for therapeutic use. This objective encompasses a dual mechanism: reduction in the ability of RSV G-protein to distort the host innate immune response, and direct complement-mediated antiviral activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available